Commentary
What to Do When There’s a Covid-19 Vaccine Glut
The Food and Drug Administration announced new steps last week to help ensure that Covid-19 tests, treatments and vaccines stay ahead of new, potentially more transmissible and virulent, variants, whose emergence makes widespread vaccination even more urgent. The longer it takes to get the virus under control, the harder it may become. And soon, the problem may be a vaccine glut if demand is weaker than expected.
After early challenges, vaccine delivery is keeping up with supply. But by the end of March, the monthly vaccine supply may reach 100 million doses. To keep pace, the vaccination rate would have to double and then some. This will require an all-of-the-above approach to administering vaccines, tapping substantial capacity in pharmacies, primary-care practices and other trusted health-care providers.
Read the full article here.
Duke-Margolis Authors
Mark McClellan, MD, PhD
Director of the Duke-Margolis Institute for Health Policy
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty